Evidence map›Paper›PMID 31637762›Full record

ArticleStatistics in medicine2019

Personalized treatment selection using data from crossover designs with carry-over effects.

Chathura Siriwardhana, K B Kulasekera, Somnath Datta

Abstract read
In one paragraph

Article in Statistics in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chathura SiriwardhanaDepartment of Quantitative Health Sciences, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii.ORCID 0000-0002-5424-003X
K B KulasekeraDepartment of Bioinformatics & Biostatistics, University of Louisville, Louisville, Kentucky.ORCID 0000-0001-7938-7217
Somnath DattaDepartment of Biostatistics, University of Florida, Gainesville, Florida.ORCID 0000-0003-4381-1842

Funding

The Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Jerris Robert Hedges · 2017 to 2026
$59.5M
RESEARCH DESIGN AND BIOSTATISTICS COREU54MD007584 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI HEDGES, JERRIS ROBERT, MOKUAU, NOREEN · 2012 to 2018
$21.1M
A Novel Analysis Plan for the Caries and Fluorosis Data from the Iowa Fluoride StudyR03DE026757 · NIDCR · UNIVERSITY OF FLORIDA · PI DATTA, SOMNATH · 2018 to 2019
$332k
NIDCR NIH HHS R03 DE026757NIMHD NIH HHS U54 MD007584NIMHD NIH HHS U54 MD007601
6 · The paper itself

Abstract

In this work, we propose a semiparametric method for estimating the optimal treatment for a given patient based on individual covariate information for that patient when data from a crossover design are available. Here, we assume there are carry-over effects for patients switching from one treatment to another. For the K treatment (K ≥ 2) scenario, we show that nonparametric estimation of carry-over effects can have the undesirable property that comparison of treatment means can only be done using independent outcome measurements from different groups of patients rather than using available joint measurements for each patient. To overcome this barrier, we compare probabilities of outcome variable of each treatment dominating outcome variables for all other treatments conditional on patient-specific scores constructed from patient covariates. We suggest single-index models as appropriate models connecting outcome variables to covariates and our empirical investigations show that frequencies of correct treatment assignments are highly accurate. The proposed method is also rather robust against departures from a single-index model structure. We also conduct a real data analysis to show the applicability of the proposed procedure.

Indexed as

Cross-Over StudiesModels, StatisticalBiostatisticsClinical Trials as TopicComputer SimulationDiabetes Mellitus, Type 2Glycated HemoglobinHumansPrecision MedicineProbabilityRandomized Controlled Trials as TopicTreatment OutcomeGlycated Hemoglobinhemoglobin A1c protein, humancrossover designsdesign variablespersonalized treatmentsprecision medicinesingle-index models

Identifiers

PMID31637762
PMCPMC6842056

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.